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Abstract: With the growing success of controlling malaria in Sub-Saharan Africa, the incidence of
fever due to malaria is in decline, whereas the proportion of patients with non-malaria febrile illness
(NMFI) is increasing. Clinical diagnosis of NMFI is hampered by unspecific symptoms, but early
diagnosis is a key factor for both better patient care and disease control. The aim of this study was
to determine the arboviral aetiologies of NMFI in low resource settings, using a mobile laboratory
based on recombinase polymerase amplification (RPA) assays. The panel of tests for this study was
expanded to five arboviruses: dengue virus (DENV), zika virus (ZIKV), yellow fever virus (YFV),
chikungunya virus (CHIKV), and rift valley fever virus (RVFV). One hundred and four children aged
between one month and 115 months were enrolled and screened. Three of the 104 blood samples
of children <10 years presented at an outpatient clinic tested positive for DENV. The results were
confirmed by RT-PCR, partial sequencing, and non-structural protein 1 (NS1) antigen capture by
ELISA (Biorad, France). Phylogenetic analysis of the derived DENV-1 sequences clustered them with
sequences of DENV-1 isolated from Guangzhou, China, in 2014. In conclusion, this mobile setup
proved reliable for the rapid identification of the causative agent of NMFI, with results consistent
with those obtained in the reference laboratory’s settings.
Keywords: fever; NMFI; mobile laboratory; RPA; DENV
1. Introduction
In Africa, fever is the most common symptom leading patients to seek health care [1,2]. Fever of
unknown origin has long served as an entry point for the treatment of malaria [3]. With encouraging
gains in malaria control in Sub-Saharan African countries, the incidence of this disease is in decline,
leading to a decreasing proportion of febrile illness attributable to malaria. Between 2000 and 2013,
malaria mortality rates decreased by 47% globally, and by 54% in sub-Saharan Africa—the region
most affected by the disease—whereas the proportion of patients presenting with non-malaria febrile
illness (NMFI) increased, respectively [4]. Acute febrile episodes are caused by various bacterial
and viral pathogens, and infections with these agents result in patients presenting with malaria-like
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symptoms [5]. Although resulting in a higher mortality than malaria, NMFIs are not being reliably
diagnosed due to the lack of accurate, rapid and affordable diagnostic tests, and also due to poor access
to diagnostics facilities in many resource-poor endemic settings [1,6,7]. The objective of this study was
to determine potential arboviral etiologies of NMFI in children in a low resource setting, using mobile
recombinase polymerase amplification (RPA)—a real-time isothermal amplification technique [8].
For this purpose, we conducted a prospective arbovirus investigation in children seeking healthcare,
at a health centre in the Dakar suburb of Medina Gounass, during a period of six months—from
September 2015 to March 2016. The mobile suitcase laboratory has also been successfully used for
Ebola virus detection [9].
2. Materials and Methods
2.1. Study Site
For a pilot study, prospective molecular screening on NMFI was conducted between September
2015 and March 2016, at the “Institut de pédiatrie sociale”, located in the suburb of Dakar (Figure 1)—the
capital city of Senegal, West Africa. Built in 1971, this health centre located at Pikine-Guediawaye has
an outpatient department with care activities focused on mother and child health. It is also involved
in the national program on immunization, in nutritional programs and in family planning. With 22
qualified staff, the health centre has 6 consultation rooms (including one for vaccination), a laboratory
and a nutritional service. With around 1,000,000 inhabitants, Pikine-Guediawaye is an agglomeration
of well-established traditional villages, and interspersed recent settlements, the latter mostly located in
flood-prone areas, where housing is officially forbidden. The western part of these towns is located
on the edge of a vast area of permanent marshland (Grande Niaye), where natural marshy hollows
and furrows dug for market garden irrigation, as well as areas of prolonged stagnation of rainwater,
are observed year-round. With a high density of housing (9200 inhabitants/km) in proximity to stretches
of water and stagnant wetlands, the population lives in an under-serviced peripheral area, in crowded
conditions, with poor water supply and sanitation, and dirt paths between dwellings and open sewers.
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2.2. Patient Selection
Children less than 10 years old were enrolled if they met the following criteria: acute fever
(≥37.5 ◦C axillary temperature), negative for malaria rapid diagnostic tests (RDTs) and living in the
same area for four successive calendar months. Regarding the eligibility for enrolment, the study
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information was read to the legal guardian, and after obtaining informed consent, clinical symptoms
were recorded, and 2 mL of venal blood was collected. The study initially consisted of a weekly
visit every Monday, before Friday was added to compensate for the small sampling observed at the
beginning of the survey.
2.3. Screening Procedure in the Field
Blood samples were collected and processed on site, using a mobile suitcase laboratory for viral
identification. The mobile laboratory consisted of a glovebox (Bodo Koennecke, Berlin, Germany),
a lab-in-a-suitcase [9–11], a solar panel and a power pack set (Yeti 400 set, GOALZERO, South
Bluffdale, UT, USA, Figure 2). The mobile setup was organized into 2 stations: the extraction
station with the glovebox, and the RPA in the suitcase laboratory. Inactivation and extraction of the
samples were performed in the glovebox using a modified protocol of the Speedxtract kit (Qiagen,
Lake Constance, Germany).
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The extraction was performed by adding 100 µL of lysis buffer, 20 µL of sera and 30 µL of magnetic
beads to a 1.5 mL tube, followed by incubation at 95 ◦C for 10 min. After incubation, the tube was
transferred to a magnetic stand for 2 min, and after sedimentation of the beads, a 150 µL volume
of supernatant was collected in a new 1.5 mL tube. RNA amplification of all samples was carried
out using the Tubescanner poi t of care device (Qiagen, Hilden, Germany), and the Twist exo RT kit
(TwistDx, Cambridge, UK), using RPA amplicons designed for the detection of 5 arbovi uses: d ngue
virus (DENV), with two sets of primers and probes (set 1 for DENV1-3 and set 2 for DENV- 4 [10]);
yellow fever virus (YFV) [12]; chikungunya virus (CHIKV) [13]; rift valley fev r virus (RVFV) [14];
and zika virus (ZIKV) [15], with analytical sensitivities of 241, 14, 10, 23, , 1; and RNA molecules
were det cted, respectively. RT-RPA reactions w re performed in a volume of 50 µL. Briefly, a mix
containing 29.5 µL of rehydration buffer, 7.2 µL of ddH2O, 420 nM of each primer, and 210 nM of
a target specific RPA exo-probe, was dispensed into each of the eight 1.5 mL tubes, before adding
5 µL of RNA template. Finally, 46.5 µL of master mix/template solution was transferred to each
lyophilized RPA pellet of the eight-tubes strip provided in the kit. An amount of 3.5 µL magnesium
acetate (280 mM) was added into the lid of each tube, before closing it and spinning the drop into the
reaction mix. For real-time fluorescence monitoring, the reaction tubes were placed in the ESE Quant
Tubescanner (Qiagen Lake Con- stance GmbH, Stockach, Germany).
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2.4. Standard Assays in the Central Laboratory
All of the samples collected in the field were shipped to the WHO collaborating centre for
arboviruses and haemorrhagic fever viruses, at the Institut Pasteur de Dakar (IPD), in order to perform
complementary confirmatory tests.
2.4.1. RNA Extraction and Real-Time qPCR
Viral RNA was extracted from 100 µL of human sera, using the QIAmp viral RNA kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. The reduced input of 100 µL serum for
this kit had been validated in-house. The RNA was eluted in 60 µL of elution buffer and placed on ice.
To confirm the detection obtained in the field, real-time RT-qPCR assays for DENV [16], CHIKV [17],
RVFV [18], YFV [19], ZIKV [20] were performed using the Quantitect Probe RT-PCR Master Mix
(Qiagen). Briefly, the detection was performed using ABI7500, using the following temperature profiles
for all RT-qPCR assays: RT at 50 ◦C for 10 min, activation at 95 ◦C for 15 min and 45 cycles of 2-step
PCR— at 95 ◦C for 15 sec and 60 ◦C for 1 min.
2.4.2. Non-Structural Protein 1 (NS1) Antigen Capture
The NS1 antigen assay was performed using the PlateliaTM Dengue NS1 Ag-ELISA kit (Biorad
Laboratories, Marnes-La-Coquette, France), according to the manufacturer’s instructions. The capture
and revelation steps were performed using a murine monoclonal antibody (MAb). The presence of
the NS1 antigen in a sample was assessed by the formation of an immune-complex MAb-NS1-MAb
(peroxidase). Briefly, 50 µL of the serum sample, 50 µL of the sample diluent (Diluent R7), and 100 µL
of the diluted conjugate were added to each well precoated with the anti-NS1 monoclonal antibody.
For each assay, positive and negative controls, as well as calibrator sera, were included. The plate was
incubated for 90 min at 37 ◦C. After six wash steps—using 250 µL of washing solution (R2)—160 µL
of tetramethylbenzidine (TMB) substrate was added to each of the wells, and the plate was further
incubated at room temperature for 30 min in the dark, followed by the addition of 100 µL of stop
solution (1N H2SO4). With the spectrophotometer optical density (OD) readings were measured at
wavelengths of 450 nm/620 nm, were obtained and the index of each sample was calculated with
the ratio OD of samples/OD of calibrators. Sample ratios <0.5, between 0.5 and 1.0, and >1.0 were
classified as negative, equivocal, and positive, respectively.
2.4.3. ELISA IgM Detection
We determined the presence of DENV, YFV, RVFV, CHIKV and ZIKV IgM in our samples by
a capture enzyme-linked immunosorbent assay (MAC ELISA), following a published protocol [21].
For the coating step, a monoclonal capture antibody (anti human IgM) was added to a 96-well
microtiter plate, and incubated at 4 ◦C overnight. The human sera were heat-inactivated (56 ◦C, 30 min),
and screened at a dilution of 1:100 in phosphate-buffered saline (PBS), supplemented with 0.05% Tween
and 1% milk powder. After washing the plate three times with PBS plus 0.05% Tween 20, a 1/100
dilution of the different serum samples and controls were added in duplicate to the plate and incubated
at 37 ◦C for 1 h. The wells were washed three times, specific and non-specific antigens were deposited,
and the plate was incubated for 1 h at 37 ◦C. After another washing step, the specific immune ascites
were added to each well. After incubation and washing, a conjugate (peroxidase labelled antibody
specific to mouse IgG) was added and allowed to react for 1 h at 37 ◦C. A tetra-methylbenzidine
(TMB) substrate was added to the IgM conjugate complex, and the coloration reaction was stopped
with sulphuric acid. The intensity of the coloration was proportional to the level of virus specific
antibodies present in the serum. An ELISA microplate reader showed the optical density (OD) of the
absorbance—an OD unit ≥ 0.2 was defined as a positive IgM.
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2.4.4. Viral Isolation and Immunofluorescence Indirect Assay
Virus isolation was attempted for samples positive with RPA/RT-qPCR. A 200 µL sample was
diluted at 1:10 in a Leibovitz 15 medium (L15), then added to a 25 cm2 flask monolayer of C6/36 cell line
at 80% confluence, followed by incubation at 28 ◦C for 1 h, to allow virus adsorption. After incubation,
the L15 medium containing 5% FBS, 1% penicillin streptomycin, and 0.05% de fungizone, was added
to the flask and incubated for 10 days, or until observation of a cytopathic effect (CPE). To assess viral
infection, indirect immunofluorescence (IFA) was conducted as previously described [22]. The flask
content was transferred to a 15 mL tube, and clarified by low-speed (2500 rpm) centrifugation at 4 ◦C
for 5 min. The supernatant was harvested and stored at −80 ◦C, while the cells were washed three
times in PBS 1×, resuspended in 4 mL of PBS 1×, and then dispensed onto a glass slide. After complete
drying, the cells were fixed in cold (−20◦) acetone for 20 min. Staining was performed with a DENV
specific hyper-immune mouse ascitic fluid, diluted at 1/40 in PBS 1×, as the first antibody. Then,
the cells were incubated for 30 min with the second antibody (1/40 goat anti-mouse IgG, 1/100 Evan’s
blue, diluted in PBS 1×). The slides were observed with a fluorescence microscope (Eurostar III plus,
Euroimmune).
2.4.5. RT-PCR Amplification, Sequencing and Phylogenetic Analysis
To define the serotype of the isolated DENV strains, viral RNA was extracted from 200 µL of
DENV infected C6/36 culture supernatant, using the QIAmp viral RNA kit (Qiagen, Hilden, Germany)
in accordance with the manufacturer’s instructions. The C-prM gene was amplified using the primers
(DS1/DS2) described by Lanciotti et al. [23]. For cDNA synthesis, 10 µL of viral RNA was mixed with
1 µL of the random hexamer primer (2 pmol), and the mixture was heated at 95 ◦C for 2 min. The reverse
transcription was performed in a 20 µL mixture containing 2.5 U RNasin (Promega, Madison, WI,
USA), 1 µL of deoxynucleotide triphosphate (dNTP) (10 mM each DNTP), and 5 U of AMV reverse
transcriptase (Promega, Madison, WI, USA), which was incubated at 42 ◦C for 60 min. The PCR
products were generated using DS1/DS2 primers at 10 µM concentration. Five microliters of cDNA
were mixed with 10× buffer, 3 µL of each primer, 5 µL of dNTPs 10 mM, 3 µL of MgCl2, and 0.5 µL of
Taq polymerase (Promega, Madison, WI, USA). Amplicons of the expected size (520 bp) were purified
from the agarose gel, with the QiaQuick Gel Extraction Kit (Qiagen, Hilden, Germany), as specified
by the manufacturer. Both strands of each amplicon were Sanger sequenced out-of-house (Genewiz,
Germany). The sequences were merged using EMBOSS Merger software, and final results were
analyzed using the Basic Local Alignment Search Tool (BLAST, www.ncbi.nlm.nih.gov/) consulted on
18 July 2017. The nucleotide sequence alignments were generated using the ClustalW algorithm, and
Maximum likelihood (ML) trees were inferred for each serotype using Mega software version 6 [24].
3. Results
3.1. Demographic and Clinical Data
During the study period from September 2015 to March 2016, 104 children aged between 1 and 115
months were enrolled and screened for DENV, CHIKV, ZIKV, YFV, RVFV—Seventy-nine were <5 years
old, and 42 (40,38%) were male (Supplementary Data 1). Regarding clinical symptoms, the most
common symptoms after fever were, respectively, rhinorrhea (65%), cough (53%; 55/104), vomiting
(25%; 26/104), diarrhoea (25%; 25/104) and abdominal pain (25%; 26/104). Headaches were reported
only in 10% of the enrolled patients, while myalgia and arthralgia were not recorded at all (Figure 3).
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3.2. Molecular, Serologic and Antigenic Detection
Three samples (2.8%) tested positive with DENV1-3 RPA, while none of the other arbovirus
assays yielded positive results. All of the arbovirus results were confirmed by RT-PCR, with 100%
concordance. The samples of the three DENV cases were additionally tested and confirmed positive by
DENV NS1 antigen capture (Table 1). The ELISA IgM test yielded negative results in all three cases
(not shown). Virus isolation at 28 ◦C in C6/36 cells yielded non-obvious CPE ten days after inoculation.
However, two strains were successfully isolated, and isolation was confirmed by IFA (Figure S1).
The isolates were designated Medina Gounass 1 and Medina Gounass 2, respectively.
Table 1. Comparison of time detection between non-structural protein 1 (NS1), real-time recombinase
polymerase amplification (RT-RPA), and RT-PCR.
Sample
Names RT-qPCR RT-RPA
NS1 Antigen
Capture
Ct Value DetectionTime
Threshold
Time
Detection
Time D.O
Average
Detection Time
Medina
Gounass 1 29.35 79 min 6 min 6 min 6.8477 2 h
Medina
Gounass 2 27.59 75 min 5 min 5 min 7.9131 2 h
Medina
Gounass 3 26.42 72 min 5 min 5 min 9.819 2 h
3.3. Phylogenetic Analysis
Finally, the sequence of the CprM gene of the two isolates was determined and deposited in
genbank (accessions numbers MK940790 (Medina gounass 1/2015), and MK940791 (Medina gounass
1/2015)). Both strains were completely homologous (100%), with no nucleotide difference. A basic local
alignment search tool for nucleotide (BLASTN), using the obtained C-prM gene sequence, sh wed 100%
identity with the DENV-1 isolates collected in Guangzhou, China, i 2014 (KP279753.1). A calculated
phylogenetic tree clustered the determined DENV-1 sequences with Asian strains, supported by high
bootstrap values (Figure 4).
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4. Discussion
The objective of this study was to assess the use of a mobile suitcase laboratory for the routine
testing of arboviral etiologies of NMFI in n outpatient clinic of a sub rb of Dakar, Senegal. During he
six month survey of arb viral infections i febrile non malaria patients, th ee cases of dengue infection
were detected in 104 enrolled childre under 10 years old.
N e of the targ ted arboviruses (CHIKV, RVFV, YFV, ZIKV) except for DENV were detected
during this study. The prev lence of DENV was 2.8%.
In a previous study on th etiology of acute febrile illness in Abidjan, an inter epidemic DENV
prevalence of 0.4% was repor ed in the 812 p tients tested [25]. Similarly, our work highlights an inter
e idemic irculation of DENV in poor urban settings of Dakar The difference in prevalence between
the two studies may be attributable t the f ct that the study conducted in Abidjan was not limi ed to
c ildren ≤10 y ars of ag , as well as the smaller number of enrolled patients in our study (104 patien s).
The border between interepidemic and pidemic prevalence i sub-Sah ra Africa is difficult to
assess, as noted by a study on febrile patients in Ibadan, Nigeria [26], which determined a prevalence of
35% of dengue infection through NS1 antigen detection. The infected patients secrete large quantities
of oluble NS1 (sNS1) into the loodstream, with co centrat ons of up to 50 µg/mL [27]. Soluble
NS1 (sNS1) ca remain in the blo d for 9 days, and persis for up to 18 days in some patients [28],
exceeding viremia which la ts up to 6 days. Thi m kes NS1 a good biomarker of acute illness as it
pr vides a wide window for DENV detecti n. It has been suggested that combining NS1 detection with
IgM detectio can outperform PCR [29]; however, t e use of NS1 detection n the routine screening
in dengue epidemics, as a prerequisite for hospitalization, has b en questioned [30]. Additionally,
fieldable ELISA systems which would allow for a comparis n between the ratios of DENV NS1-Ag
and DENV-RNA, are not c rrently avail ble.
Phylogenetic analysis of the obtained DENV C-prM gene sequences yielded 100% identity with
the isolates collected in Guangzhou, China, in 2014. A calculated phylogenetic tree clustered the
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determined DENV-1 sequences with Asian strains, supported by high bootstrap values (Figure 4).
This finding suggests an importation of the virus to Senegal from Asia, via acutely viremic cases or
by infected mosquitoes or their eggs. Indeed, in recent years, international travel and trade activity
between the Asian and African continents has increased considerably [31]—between 1994 and 2009,
the annual volume of trade between Senegal and China grew from 23 million U.S. dollars to 441 million
U.S. dollars, representing a twenty-fold increase in 15 years [32]. The potential to extend the distribution
area of individual arboviruses was recently supported by the detection of Japanese encephalitis virus
(JEV), during a yellow fever outbreak in Lunda (Angola), in 2016 [33]. This virus is endemic in Asia
and the western pacific, but local circulation had never been documented before in Africa [34]. Another
example is the first case of RVFV infection, detected in China from a patient returning from Angola in
2017—while this virus was previously restricted to sub-Saharan Africa, it has been spreading in the
Arabic peninsula since 2000 [35].
In Africa, dengue is likely to be underreported and under-recognized. This is due to the low
awareness of health care providers, and the circulation of other prevalent NMFI [5]. The absence of
surveillance in many African countries and the lack of effective diagnostic tools also contribute to the
underestimation of the real incidence of dengue fever in Africa [31]. Since other studies report the
expansion of dengue fever among NMFI [36], our study and the cited studies in Abidjan and Ibadan
stress the need to implement laboratory capacity to assess the real burden of DENV in rural and urban
areas of West Africa, during inter epidemic periods.
The RPA positive samples were confirmed by serological assay, viral isolation as well as
real-time RT-PCR. The laboratory-based real-time RT-PCR and mobile RT-RPA results were concordant,
but mobile RT-RPA yielded results in approximately 20 min, including the extraction step (Table 1).
Additionally, the RPA was performed at the point of need in a suitcase laboratory. In conclusion,
although virus isolation remains the “gold standard” in diagnostics [37], rapid molecular testing at the
point of care can provide reliable results (short time-length process, sensitivity and specificity).
5. Conclusions
Our results suggest that the RT-RPA could be an alternative to real-time PCR in low resource
settings. This field deployment contributed to the evaluation of the feasibility to implement point of
need arbovirus diagnostics in primary care settings and showed that RT-RPA can be a reliable and
accurate diagnosis tool for the detection of NMFI in low-income settings. However, studies with larger
cohorts are needed.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4418/10/6/408/s1,
Figure S1: Assessment of Dengue virus infection using immunofluorescence Indirect Assay (IFA) on C6/36 cells
infected with 200 µL of crushed mouse brain previously inoculated with Positive Sera. Immune Ascite fluid was
used as the Primary antibody (A: Negative control, B: Medina Gounass 1, C: Medina Gounass 2), Supplementary
Data 1: Data table supporting the findings.
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